Published in Lancet on January 24, 2004
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol (2006) 1.71
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2016) 1.58
Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol (2005) 1.38
Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol (2008) 1.32
Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) (2013) 1.14
Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis (2007) 1.13
Well-characterized monoclonal antibodies against cell wall antigen of Aspergillus species improve immunoassay specificity and sensitivity. Clin Vaccine Immunol (2007) 0.98
Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol (2005) 0.97
Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis (2005) 0.82
Clinical utility and development of biomarkers in invasive aspergillosis. Trans Am Clin Climatol Assoc (2011) 0.81
Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol (2005) 0.80
Fungal infections: their diagnosis and treatment in transplant recipients. Int J Hepatol (2012) 0.79
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag (2008) 0.79
Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature. BMC Infect Dis (2017) 0.75
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Nitrite-driven anaerobic methane oxidation by oxygenic bacteria. Nature (2010) 4.06
Deciphering the evolution and metabolism of an anammox bacterium from a community genome. Nature (2006) 4.06
A microbial consortium couples anaerobic methane oxidation to denitrification. Nature (2006) 3.84
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis (2004) 3.02
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol (2011) 2.32
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
Evidence for complete denitrification in a benthic foraminifer. Nature (2006) 2.24
High-level functional expression of a fungal xylose isomerase: the key to efficient ethanolic fermentation of xylose by Saccharomyces cerevisiae? FEMS Yeast Res (2003) 2.17
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 2.09
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Azole-resistant central nervous system aspergillosis. Clin Infect Dis (2009) 1.94
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis (2003) 1.91
Methanotrophy below pH 1 by a new Verrucomicrobia species. Nature (2007) 1.88
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Denitrifying bacteria anaerobically oxidize methane in the absence of Archaea. Environ Microbiol (2008) 1.80
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis (2006) 1.79
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One (2010) 1.77
Molecular mechanism of anaerobic ammonium oxidation. Nature (2011) 1.73
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis (2009) 1.73
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 1.71
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Anammox bacteria disguised as denitrifiers: nitrate reduction to dinitrogen gas via nitrite and ammonium. Environ Microbiol (2007) 1.65
Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol (2006) 1.64
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis (2013) 1.59
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol (2003) 1.59
Multidrug resistance in Aspergillus fumigatus. N Engl J Med (2002) 1.54
Biochemistry and molecular biology of anammox bacteria. Crit Rev Biochem Mol Biol (2009) 1.53
Methanotrophic symbionts provide carbon for photosynthesis in peat bogs. Nature (2005) 1.53
Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol (2002) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell (2008) 1.46
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother (2010) 1.45
The metagenome of the marine anammox bacterium 'Candidatus Scalindua profunda' illustrates the versatility of this globally important nitrogen cycle bacterium. Environ Microbiol (2012) 1.44
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis (2008) 1.43
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol (2008) 1.43
Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw (2006) 1.41
Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol (2010) 1.37
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis (2005) 1.36
Whole-genome analysis of the ammonia-oxidizing bacterium, Nitrosomonas eutropha C91: implications for niche adaptation. Environ Microbiol (2007) 1.36
Aspergillosis--and a misleading sensitivity result. Lancet (2007) 1.36
1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med (2006) 1.35
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol (2005) 1.34
Aspergillus species intrinsically resistant to antifungal agents. Med Mycol (2010) 1.33
Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis (2004) 1.33
Autotrophic methanotrophy in verrucomicrobia: Methylacidiphilum fumariolicum SolV uses the Calvin-Benson-Bassham cycle for carbon dioxide fixation. J Bacteriol (2011) 1.26
Genome sequence of the obligate methanotroph Methylosinus trichosporium strain OB3b. J Bacteriol (2010) 1.24
Rare earth metals are essential for methanotrophic life in volcanic mudpots. Environ Microbiol (2013) 1.24
PQQ-dependent methanol dehydrogenases: rare-earth elements make a difference. Appl Microbiol Biotechnol (2014) 1.23
Diversity and enrichment of nitrite-dependent anaerobic methane oxidizing bacteria from wastewater sludge. Appl Microbiol Biotechnol (2011) 1.23
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One (2012) 1.22
Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis (2004) 1.22
Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health (2006) 1.22
Serpins in prokaryotes. Mol Biol Evol (2002) 1.22
Aspergillus fumigatus conidial melanin modulates host cytokine response. Immunobiology (2009) 1.21
pmoA Primers for detection of anaerobic methanotrophs. Appl Environ Microbiol (2011) 1.20
Ladderane phospholipids in anammox bacteria comprise phosphocholine and phosphoethanolamine headgroups. FEMS Microbiol Lett (2006) 1.20
Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat (2012) 1.19
B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood (2011) 1.19
Co-occurrence and distribution of nitrite-dependent anaerobic ammonium and methane-oxidizing bacteria in a paddy soil. FEMS Microbiol Lett (2012) 1.18
Hydrazine synthase, a unique phylomarker with which to study the presence and biodiversity of anammox bacteria. Appl Environ Microbiol (2011) 1.18
Propionate oxidation by and methanol inhibition of anaerobic ammonium-oxidizing bacteria. Appl Environ Microbiol (2005) 1.17
Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol (2008) 1.17
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol (2006) 1.16
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol (2012) 1.16
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol (2003) 1.15
Xylose metabolism in the anaerobic fungus Piromyces sp. strain E2 follows the bacterial pathway. Arch Microbiol (2003) 1.15
Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol (2011) 1.14
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 1.13
A comparative genomics study of genetic products potentially encoding ladderane lipid biosynthesis. Biol Direct (2009) 1.13
Environmental detection of octahaem cytochrome c hydroxylamine/hydrazine oxidoreductase genes of aerobic and anaerobic ammonium-oxidizing bacteria. Environ Microbiol (2008) 1.11
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
How to make a living from anaerobic ammonium oxidation. FEMS Microbiol Rev (2013) 1.09
Extreme growth failure is a common presentation of ligase IV deficiency. Hum Mutat (2013) 1.08
Nitrogen fixation by the verrucomicrobial methanotroph 'Methylacidiphilum fumariolicum' SolV. Microbiology (2010) 1.08
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother (2008) 1.07
Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus. Infect Immun (2009) 1.06
Promicromonospora pachnodae sp. nov., a member of the (hemi)cellulolytic hindgut flora of larvae of the scarab beetle Pachnoda marginata. Antonie Van Leeuwenhoek (2003) 1.06
Diversity and abundance of aerobic and anaerobic ammonium-oxidizing bacteria in freshwater sediments of the Xinyi River (China). Environ Microbiol (2007) 1.05
Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis (2008) 1.05
In vitro susceptibilities of Zygomycota to polyenes. J Antimicrob Chemother (2002) 1.05
The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol (2011) 1.05
Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. Am J Respir Crit Care Med (2013) 1.05
Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother (2002) 1.05
Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am (2006) 1.04
Draft Genome Sequence of Methylomicrobium buryatense Strain 5G, a Haloalkaline-Tolerant Methanotrophic Bacterium. Genome Announc (2013) 1.04